XinThera focuses on discovering small-molecule therapeutics across oncology and immunology. The company has assembled a team with decades of experience that has contributed to more than seven marketed drugs and dozens of clinical compounds. XinThera has progressed rapidly since its seed financing in February 2021 and emphasizes a global strategy including connections to the China market. Its leadership includes co-founder and chairman Stephen Kaldor (with 25+ years of experience), co-founder and CSO Qing Dong, and co-founder Gene Hung. The firm plans to use recent financing to support recruiting and to build out its product pipeline. XinThera is based in San Diego, CA.

Total raised

$50M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2021